Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-12-02 am EST
38.04 EUR   -0.11%
11/11European Medicines Agency Panel Adopts Recommendation for Galapagos' Jyseleca Product Label
MT
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following extensive safety review of all JAK inhibitors
GL
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following extensive safety review of all JAK inhibitors
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Real-time Quote. Real-time Euronext Amsterdam
11/28/2022 11/29/2022 11/30/2022 12/01/2022 12/02/2022 Date
39.15(c) 37.96(c) 38.11(c) 38.08(c) 38.04(c) Last
146 589 248 230 251 023 122 094 119 891 Volume
-0.28% -3.04% +0.40% -0.08% -0.11% Change
More quotes
Estimated financial data (e)
Sales 2022 551 M 579 M 579 M
Net income 2022 -49,1 M -51,6 M -51,6 M
Net cash position 2022 4 166 M 4 373 M 4 373 M
P/E ratio 2022 -90,3x
Yield 2022 -
Sales 2023 557 M 585 M 585 M
Net income 2023 -158 M -165 M -165 M
Net cash position 2023 2 861 M 3 003 M 3 003 M
P/E ratio 2023 -18,5x
Yield 2023 -
Capitalization 2 507 M 2 631 M 2 631 M
EV / Sales 2022 -3,01x
EV / Sales 2023 -0,64x
Nbr of Employees 1 357
Free-Float 73,8%
More Financials
Company
Galapagos NV specializes in the research and development of drugs based on novel targets discovered and validated in human primary cells. Net sales break down by source of income as follows: - sales of collaboration services (97%). Net sales are distributed geographically between Europe (99.6%) and the United States (0.4); - sales of products (3%). 
More about the company
Ratings of Galapagos NV
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GALAPAGOS NV
11/11European Medicines Agency Panel Adopts Recommendation for Galapagos' Jyseleca Product L..
MT
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following exte..
GL
11/11Galapagos announces CHMP adoption of PRAC's recommendation for Jyseleca« following exte..
AQ
11/11Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca« Following..
CI
11/08Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
GL
11/08Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study..
AQ
11/08Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis st..
CI
11/07RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating
MT
11/04Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022
CI
11/04Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
GL
11/04Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
AQ
11/04Transcript : Galapagos NV, Q3 2022 Earnings Call, Nov 04, 2022
CI
11/03Galapagos announces strategy to accelerate innovation and reports strong third quarter ..
GL
11/03Galapagos NV Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
10/17Galapagos : Press release dated October 17, 2022 - Form 6-K
PU
More news
News in other languages on GALAPAGOS NV
11/16Barclays verlaagt koersdoel Galapagos
11/11Galapagos ontvangt aanbeveling over maatregelen voor Jyseleca
11/11Le panel de l'Agence européenne des médicaments adopte une recommandation pour l'étique..
11/11Galapagos kondigt aan dat het CHMP de aanbeveling van het PRAC voor Jyseleca« heeft ove..
11/11Galapagos kondigt aan dat het CHMP de aanbeveling van het PRAC voor Jyseleca« heeft ove..
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
ETFs positioned on GALAPAGOS NVETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Vectors AMX - EUR3.95%0.16%dutch
Lyxor BEL 20 TR (DR) - Dist - EUR1.9%-0.29%Belgium
UBS ETF - MSCI EMU Small Cap A-dis - EUR0.49%-0.39%Europe
Lyxor MSCI EMU Small Cap (DR) - Dist - EUR0.49%0.04%Europe
IShares MSCI Europe Small-Cap ETF - USD0.19%1.80%Europe
More ETFs positioned on GALAPAGOS NV
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 38,08 €
Average target price 55,00 €
Spread / Average Target 44,4%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-22.63%2 587
MODERNA, INC.-28.55%67 581
IQVIA HOLDINGS INC.-21.83%40 495
LONZA GROUP AG-33.17%38 281
ALNYLAM PHARMACEUTICALS, INC.29.88%27 139
SEAGEN INC.-21.72%22 538